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Oxalosis as a complication of chronic renal failure. The occur-
rence of renal and myocardial calcium oxalate deposition was
studie at autopsy in patients with normal renal function, acute
renal failure, chronic renal failure, and chronic renal failure
supported by hemodialysis or peritoneal dialysis. The incidence
and severity of this type of secondary oxalosis was found to be
related to the duration of renal failure. Patients with renal failure
of long duration frequently had extensive renal and myocardial
deposits. Hemodialysis may ameliorate the oxalosis to some
extent.
Oxalose complication de l'insuffisance rénale chronique. La
survenue de dépôts rénaux et myocardiaques d'oxalate de calcium
a été étudiée a l'autopsie de malades dont Ia fonction rénale
était normale, ou atteints d'insuffisiance rénale aigue, d'insuffi-
sance rénale chronique, d'insuffisance rénale chronique
traitée par hémodialyse ou dialyse péritonéale. La survenue
et Ia sévérité de cette variété d'oxalose secondaire est en
relation avec Ia durée de l'insuffisance rénale. Les malades
atteints d'insuffisance rénale d'évolution longue avaient fré-
quemment des dépôts myocardiques et rénaux étendus. L'hémo-
dialyse peut apparemment améliorer dans une certaine mesure
l'oxalose.
Oxalosis, or calcium oxalate deposition in the tissues, is
classified as primary or secondary. In man, glyoxalate is
the main precursor of oxalate. Any abnormality in the
other metabolic pathways of this precursor such as enzyme
or cofactor deficiencies could result in excessive oxalate
production. The major alternate pathways of glyoxalate
metabolism involve transamination with a-ketoglutarate
(requiring thiamine), conversion to glycine (requiring
pyridoxine) and reduction to glycolate [11.
In primary oxalosis, there is excessive biosynthesis of
oxalate as a result of an enzymatic defect. At least two
different types have been characterized, both associated
with hyperoxaluria—calcium oxalate urinary tract lithiasis,
and the development of renal insufficiency at an early age
[2—4]. A third variety, in which the consequences of hyper-
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oxaluria do not become manifest until adult life, may exist
but has not been fully characterized [5, 6].
Secondary oxalosis theoretically may occur either as a
result of excessive ingestion of oxalate or oxalate pre-
cursors such as ethylene glycol [4] due to a deficiency of a
cofactor involved in oxalate metabolism such as pyridoxine
[1], or through decreased excretion of oxalate [1, 4].
Although oxalosis has been described in association with
renal insufficiency in previous studies [7—9], its relationship
to renal failure has been questioned [10].
In recent years, massive tissue deposits of oxalate have
been observed at autopsy in several patients, all of whom
had chronic renal failure of long duration. These cases
prompted the present study, which was designed to de-
termine the incidence, severity and possible etiologic factors
of oxalosis secondary to renal insufficiency in patients at
autopsy.
Marked increases in incidence and severity of renal and
myocardial oxalosis in patients with renal insufficiency
compared with control subjects were observed. The extent
of the oxalate deposits appeared to correlate with the
duration of azotemia. The oxalate deposits may have
contributed to renal parenchymal injury and were associated
with myocardial fibrosis in some patients.
Methods
The clinical histories of the patients studied were re-
viewed in order to determine a history of renal disease,
serum urea nitrogen (SUN), creatinine, and duration of
severe azotemia and dialysis. The duration of severe
azotemia was estimated using the interval between the date
a SUN determination was greater than 50 mg/lO0 ml (or a
creatinine value was greater than 3 mg/lOO ml in the chronic
renal failure groups) with no subsequent improvement
except that resulting from dialysis, and death. None of the
patients was known to have ingested substances associated
with oxalate deposition. It was impossible to totally exclude
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the possibility that some of the patients may have had
primary oxalosis, since neither urine nor plasma oxalate
determination was available. However, no patient had a
family history of oxalosis, and no patient with a history of
urinary tract calculi or calculi at autopsy was included.
The patients studied were taken from the autopsy files
of the Johns Hopkins Hospital. All of the patients died in
the six year period between January 1, 1966 and Decem-
ber 31, 1971. Group A was a control group composed of
patients with no known renal disease and a terminal SUN
reading of less than 50 mg/lOO ml. The 50 most recent pa-
tients in the six year period fulfilling these criteria were
selected. Group B consisted of the 50 most recent patients
with terminal acute renal failure, defined by the presence of
SUN greater than 50 mg/100 ml but of less than two months
duration. Group C included the 50 most recent patients
who died with chronic renal failure (SUN greater than
50 mg/I® ml or a creatinine greater than 3 mg/i® ml for
longer than two months) but no history of dialysis. Group D
was composed of all 15 patients in the autopsy files with a
history of a SUN greater than 50 mg/i® ml or a creatinine
greater than 3 mg/i® mlfor longer than two months before
death and intermittent hemodialysis for greater than two
months duration. Group E included all 15 patients in the
autopsy files with a history of a SUN greater than 50 mg-
i® ml or a creatinine greater than 3 mg/i® ml for longer
than two months before death and intermittent peritoneal
dialysis for longer than two months.
The pathologic findings and the routinely-prepared hema-
toxylin- and eosin-stained (H and F) sectionsof the kidneys
and myocardium from each case were reviewed. Calcium
oxalate crystals were identified as light yellow-brown
crystals in H and E sections. The crystals were rosette- or
diamond-shaped and exhibited strong birefringence. In
addition, the oxalate content of the crystals was confirmed
histochemically [Ii]. After a preliminary screening of all the
slides, the extent of the crystal deposition in the kidneys and
myocardium was graded subjectively by one observer,
without knowledge of the case group, on a scale of 0 to 3+.
Results
The oxalate crystals were observed in the kidney pri-
marily within the tubules in the cortex (Fig. 1). In the cases
in which the renal architecture remained relatively intact,
most crystals appeared to be located in the proximal
convoluted tubules. Occasional interstitial deposits were
seen (Fig. 2). There frequently was no inflammatory reac-
tion in either location. Slight chronic inflammation with
focal giant cells in association with the crystals was oc-
casionally observed.
In the myocardium the crystals were present both in the
interstitium and within myocardial fibers. Foci of slight
chronic inflammation with occasional giant cells and myo-
fiber necrosis were observed. The amount of reactive
fibrosis in the heart varied from slight to extensive and
paralled the amount of deposited oxalate (Fig. 3).
The results of the estimations of incidence and severity
of oxalate deposition are presented in Table 1. By definition,
the patients in Group A had a terminal SUN reading of
less than 50 mg/100 ml. The only significant renal lesions
observed in this group were mild arteriosclerosis. Four
Fig. I, A and B. Kidney with severe (3+) intratubular calcium oxalate deposition. (Hematoxylin and eosin, partially polarized light.
A, x 155, B, x 370).
Fig. 2. Tubular and interstitial calcium
oxalate deposition in the kidney. (H & E,
partially polarized x 370).
Fig. 3. Severe (3+) myocardial calci-
um oxalate deposits with marked reactive
fibrosis. (H & E, partially polarized
x 165).
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cases in this group had slight, focal deposits of oxalate in
the kidney. Myocardial involvement was not observed.
The patients in Group B had acute renal failure with
SUN determination greater than 50 mg/100 ml for less
than two months duration. Of the 50 patients, 45 had acute
tubular necrosis, two had bilateral cortical necrosis, one had
scleroderma kidney disease, one had accelerated hyper-
tension with nephrosclerosis and one had acute pyelo-
nephritis. The average duration of severe azotemia in this
group was 13 days with a range of one to 45 days. Renal
oxalosis was present in 28 cases. This was severe in five,
moderate in six, and slight in 17. Slight myocardial de-
posits were observed in four cases.
The 50 patients in Group C had chronic renal failure
with severe azotemia for longer than two months but no
dialysis. Arterio- and arteriolonephrosclerosis was the
underlying disorder in 26, chronic glomerulonephritis in
nine, obstructive chronic pyelonephritis in eight, polycystic
kidney disease in two, scleroderma in one, and Good-
pasture's syndrome in one. In three patients, the diagnosis
at autopsy was end-stage kidney disease. The average
duration of severe azotemia in this group was 15 months
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Table 1. Incidence and severity of oxalate deposition in 180 patients
Group Description No.
patients
Average age,
yr
(range)
Average time
SUN >50 mg/
100 ml or
creatinine
Degree of oxalosis
——
Myocardium
0 1 + 2+ 3 +0 Kidney1 + 2+ 3 +
>3 mg/lOOml
(range)
A Control 50 56
(7—87)
— 46 4 0 0 50 0 0 0
B Acute renal failure 50 58
(1—93)
13 days
(1—45 days)
22 17 6 5 46 4 0 0
C Chronic renal failure 50 52
(5—102)
15 mu
(2—144 mo)
8 20 10 12 45 2 1 2
D Chronic renal failure 15 37 28 mo 4 6 3 2 12 3 0 0
and hemodialysis (17—63) (5—60 mo)
E Chronic renal failure 15 23 42 mo 0 0 0 15 6 1 3 5
and peritoneal dialysis (2—49) (6—156 mo)
with a range of two to 144 months. The duration was longer
than six months in 25 cases. Oxalate deposition was present
in the kidneys in 42 of the 50 cases. It was severe in 12,
moderate in ten and slight in 20. Myocardial involvement
was present in five patients: severe in two, moderate in one
and slight in two.
The 15 patients in Group D had chronic renal failure and
also underwent intermittent hemodialysis for a two month
or longer period. The renal diseases in this group were
chronic glomerulonephritis in five, end-stage kidney disease
in five, accelerated hypertension with nephrosclerosis in
two, chronic pyelonephritis in one, lupus nephritis in one,
and Goodpasture's syndrome in one. The average duration
of severe azotemia was 28 months with a range of five to
60 months. The duration was longer than six months in all
15 cases. Oxalate crystals were observed in the kidneys of
11 of the 15 patients, being severe in two, moderate in
three and slight in six. Slight myocardial deposits were
present in only three cases.
Group E included 15 patients with chronic renal failure
who were maintained by peritoneal dialysis. Six of these
patients had chronic glomerulonephritis, three had ob-
structive chronic pyelonephritis, five had end-stage kidneys,
and one had polycystic kidney disease. The average duration
of severe azotemia for the group was 42 months with a
range of six to 156 months. The duration was longer than
six months in 13 of the 15 cases. All 15 patients had severe
oxalate deposition in the kidney. Five had severe, three had
moderate and one had slight myocardial involvement.
Statistical analysis (Chi-square) of the data indicates that
the incidence of renal oxalosis was significantly greater in
Groups B, C, D and E than in Group A (P <0.01). The
incidence was also greater in Groups C and E than in
Group B (P <0.01). The incidence of renal oxalosis was
not different in Groups B and D and in Groups C, D and E.
The severity of renal oxalosis was greater in Groups C
and E than in Group B (P <0.01) and greater in Group E
than in Groups C and D (P <0.01). The severity was not
significantly different in Groups B and D and in Groups C
and D.
The incidence of myocardial oxalosis was greater in
Group E than in Groups A, B and C (P <0.01). The dif-
ference between Groups A and C (P <0.10 >0.05), Group A
and D (Pczo.02 >0.01), and Groups D and E (P<0.l0
>0.05) approached statistical significance. There was no
significant difference in the other groups. The severity of
myocardial oxalosis was greater in Group E than in any of
the other groups (P <0.01), but the other groups did not
differ.
The average duration of severe azotemia for the seven
patients with severe myocardial involvement (five: Group E;
two: Group C) was 68 months. This differed significantly
from the average duration of the other 73 cases of Groups C,
D and E which was 18 months (P<0.01).
Impressive crystal deposits were occasionally observed in
tissues other than the kidneys and heart, although no other
site was consistently studied. The bony trabeculae of the
vertebrae revealed extensive deposits in six patients, all of
whom also had severe renal and myocardial involvement.
In two cases, massive deposits were noted in the media of
the splenic artery.
Discussion
This study indicates that secondary oxalosis in associa-
tion with renal insufficiency is frequent and often extensive.
In addition, the incidence and severity of the oxalate de-
position appears to be related to the duration of renal
insufficiency. These observations support the assumption
that plasma oxalate levels rise as renal insufficiency de-
velops since renal excretion is the only outlet for oxalate
produced in man [4]. Although oxalate levels were not
measured in these patients, it seems reasonable to expect
elevated plasma concentrations and tissue deposits when
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the solubility product of calcium oxalate in plasma is
exceeded [121. In patients with primary hyperoxaluria, it is
generally thought that extrarenal oxalosis develops pri-
marily after the onset of renal insufficiency [4].
Although Hockaday et al [4] did not observe elevated
plasma oxalate concentrations in patients with azotemia,
Zarembski, Hodgkinson and Parsons [13], with newer
techniques, found increased levels in 11 of 15 azotemic
patients.
Repeated measurements of plasma calcium concentra-
tions were available in only a small number of these pa-
tients. Thus, the possibility that fluctuations in plasma
calcium levels contribute to secondary oxalosis cannot be
excluded. This seems unlikely, however, and we are una-
ware of reports of oxalosis in association with other causes
of abnormal plasma calcium concentration.
Deposits of calcium phosphate were observed in both
the kidneys and myocardium of only a small number of the
patients in this series. When present, it appeared to have
no relationship to the crystals of calcium oxalate. The
possibility that calcium phosphate deposition was necessary
for oxalosis to occur seems excluded by the rarity with
which the two were observed together.
Deposits of calcium oxalate in the kidneys and myocar-
dium have been reported previously in association with
renal insufficiency [7—9], However, Bennington et al [10]
were unable to document an increased incidence of oxalosis
in azotemic patients compared with controls.
In the present study, both the incidence and severity of
renal oxalosis increased as duration of renal insufficiency
increased. Renal oxalate deposits in patients with acute
renal failure were less common and much less extensive
than in patients with azotemia of longer duration. In
addition, within the groups with chronic renal failure, the
severity of renal oxalosis increased. Myocardial oxalate
deposits were uncommon except in patients with long-
standing azotemia. The severity of myocardial oxalosis also
appeared to be related to the duration of azotemia.
The patients with chronic renal failure who were on
hemodialysis were an exception. The duration of severe
azotemia was longer than six months in all 15 patients, and
the average duration of renal insufficiency in this group was
intermediate of the three chronic renal failure groups.
However, the extent of renal oxalosis was not different
from the acute renal failure group. This apparent sparing
of the hemodialysis group is possibly because the elevated
plasma oxalate levels are reduced by hemodialysis. The
results suggest that hemodialysis may be more effective in
lowering plasma oxalate levels than peritoneal dialysis. In
one patient with primary oxalosis, Zarembski et al [14] ob-
served no reduction in plasma oxalate concentration by
peritoneal dialysis. However, the difference in incidence
and severity of oxalate deposition in the two dialysis groups
in this study may be due to the much longer duration of
renal failure in the peritoneal dialysis group rather than to
the type of dialysis therapy.
The importance of calcium oxalate deposition in tissues
is uncertain. Renal oxalosis in patients with end-stage
kidney disease requiring dialysis is probably of no con-
sequence. However, renal parenchymal crystals and the
associated inflammation, fibrosis and possible tubular cell
injury may be of importance in patients with chronic renal
insufficiency and in patients with acute renal failure. A re-
cent report suggests that oxalate crystal deposition may
be the cause of the prolonged course of acute renal
failure occasionally associated with methoxyfluorane an-
esthesia [15].
Involvement of extrarenal tissues may be of greater im-
portance. Cardiac complications, including diffuse fibrosis
and conducting system lesions, have been described in pa-
tients with primary oxalosis [6, 16, 17]. The observation of
myofiber necrosis and fibrosis associated with oxalate
crystals suggests the possibility of similar complications in
patients with secondary oxalosis. In one case in this series,
oxalate deposits in the conducting system resulted in
complete heart block (unpublished observations).
The results of this study indicate that the incidence and
severity of secondary renal and myocardial oxalosis are
related to the duration of severe azotemia. Hemodialysis
may ameliorate the secondary oxalosis to some extent.
Deposits of calcium oxalate in the kidney and myocardium
are associated with reactive fibrosis, and the resulting
parenchymal damage may have clinical importance in some
cases.
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